Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Raw Materials: 2023-2025

Historic Raw Materials for Tg Therapeutics (TGTX) over the last 3 years, with Sep 2025 value amounting to $4.1 million.

  • Tg Therapeutics' Raw Materials rose 134.08% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 134.08%. This contributed to the annual value of $28.2 million for FY2024, which is 327.70% up from last year.
  • As of Q3 2025, Tg Therapeutics' Raw Materials stood at $4.1 million, which was down 1.46% from $4.1 million recorded in Q2 2025.
  • Tg Therapeutics' Raw Materials' 5-year high stood at $28.2 million during Q4 2024, with a 5-year trough of $24,000 in Q1 2023.
  • Moreover, its 3-year median value for Raw Materials was $1.7 million (2024), whereas its average is $4.9 million.
  • Data for Tg Therapeutics' Raw Materials shows a peak YoY skyrocketed of 7,129.17% (in 2024) over the last 5 years.
  • Tg Therapeutics' Raw Materials (Quarterly) stood at $6.6 million in 2023, then soared by 327.70% to $28.2 million in 2024, then soared by 134.08% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $4.1 million for Q2 2025, and $4.1 million during Q1 2025.